{"name":"Healthgen Biotechnology Corp.","slug":"healthgen-biotechnology-corp","ticker":"","exchange":"","domain":"healthgenbiotechnology.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"OsrHSA","genericName":"OsrHSA","slug":"osrhsa","indication":"Other","status":"phase_3"},{"name":"Plasbumin®-20","genericName":"Plasbumin®-20","slug":"plasbumin-20","indication":"Hypovolemia and shock management","status":"phase_3"}]}],"pipeline":[{"name":"OsrHSA","genericName":"OsrHSA","slug":"osrhsa","phase":"phase_3","mechanism":"OsrHSA is a recombinant human serum albumin fusion protein designed to extend the half-life and improve the pharmacokinetics of a therapeutic payload.","indications":[],"catalyst":""},{"name":"Plasbumin®-20","genericName":"Plasbumin®-20","slug":"plasbumin-20","phase":"phase_3","mechanism":"Plasbumin-20 is a human serum albumin solution that acts as a plasma volume expander and colloid to restore intravascular oncotic pressure and improve tissue perfusion.","indications":["Hypovolemia and shock management","Plasma volume restoration in critical care settings","Albumin replacement in hypoalbuminemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPQ0IyRmpWZzhoSnhlMVFEdVdtRzM2TjRtN0FfSXp5YjBSMHJVcGZwNlJxR09OODhWQWhIM3NRcV9pdEczQUhiaEs1aXpXYVlRWFlWb1k5QVVfd0t5bmQxRmVGblpDZVM4SmRtN2taaExmRU9KN3BmLU95bVRRM1V4aWtYaEZQVGpZNzRsOEVrSTdVc2FiVTFDcDJhb19DczA5M2IzM0FR?oc=5","date":"2025-12-09","type":"pipeline","source":"BioWorld News","summary":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025 - BioWorld News","headline":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQYTZURlg2TXhBdzAtNVV3b0Q3VEpHZEI4V1VqbmoybWpiTTJrSWhESjhJSkV4UHAtcHB1MzBqNllhUGQ1M21BTktDaWkyQXZ5NnZ3b1B6ZUJ6WHowQW43NzdTZlNaenlCY3RLNVc1Ti1vekQtUkpxcnRqX3VGRXhOR19tNGJTQmNkNWhJc2FqbXVablluQnlHWQ?oc=5","date":"2025-10-08","type":"pipeline","source":"C&EN","summary":"Albumin made from rice could be game changing. But can the start-up that makes it survive? - C&EN","headline":"Albumin made from rice could be game changing. But can the start-up that makes it survive? - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOSkJVaXVScmZMeUthSF9SeUw3T0Y4MHZsWTd2dmhXYVpWZmlVdkZYdzhDYlAySGlpX0s4dzUxc0FyckhCM0liZVB0NHVJU0hWZmx5ckdQRVdId0JIWDd6WmNOTndBRW5DcVRReTVuc2o0MlY4UXlvcE50dnhWY3RMV2ZfUnc5RlA0R0NTNEcyNldNSGtMZGFEd0FRQmZyQlE0OERj?oc=5","date":"2025-07-22","type":"pipeline","source":"BioWorld News","summary":"34 mainland China biotechs file for Hong Kong IPO in H1 2025 - BioWorld News","headline":"34 mainland China biotechs file for Hong Kong IPO in H1 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1ZNHdqSDlpNThzLTA4VmhNS1l0NzFxdUJwUTdjRi1Ta21sQk1Zc3JoUFdxQXVzemtVcE5LYTNBaDBVOEtSdHhHVlkwWUlRY1FYODlPYkxuMThBSFBoaGFmQXZuSGNETFlpOHFlSTczZ3B6R240bXVlR1AwYzhNZw?oc=5","date":"2024-03-14","type":"pipeline","source":"China Daily","summary":"Healthgen embraces biotech breakthrough - China Daily","headline":"Healthgen embraces biotech breakthrough","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE16Qko1cFR5eS1TNkdCVzRxLXlBaWRsWDBDTGhXNEQ4NzNDQmtUdXA5OE9VQ0oxY2c2VXB2V2twc2J0OWRPU3lsc2l1ZFFkVGNxZ1N5dnBWc3M1X003Nld6b0VCV2tib3ZqcjBibFNlT2U1MmlsbjdtdDBNdTlIZw?oc=5","date":"2019-08-13","type":"regulatory","source":"China Daily","summary":"FDA approves new biotechnology - China Daily","headline":"FDA approves new biotechnology","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE9GbkRSd3E2SmI1bzdtU1k1aURYSzRfX3FZcjVsSHNrakxIZXEtTnBUZjBzUXdOUzNwZGwtTVZ1U0lOdzgtejlsT19LRmt2UVZrYjRpN2JDVm54dVlkZHhSNUlVZm9fZUlBSHFvOG1MckVuV250bGc?oc=5","date":"2017-05-19","type":"regulatory","source":"China Daily","summary":"Trial approved for blood protein cultivated in rice - China Daily","headline":"Trial approved for blood protein cultivated in rice","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQc0gwdFJjcU03b2Rrckt6MGRlaEVwNEJ6ZTB2OWhHZGFvRWluT1JzQzJJUUtUSGhDRnNTNDNYbTdBSmtxa2x3WjBBZ2FWWjltdU9URW5tRlZTZFpTMTZVMXN3MXBpcTQ4TFQ4b2NMQ0hkc3dNd0pycERSYlB2aFZ2MmhxUllTT21PRXNkdlZZcGdsaTByU0Z0cHMwa3JhQ3psYTBSMlFlLWNfQ0E?oc=5","date":"2012-08-17","type":"pipeline","source":"BioSpectrum Asia","summary":"Using rice grains as factories for producing medicines - BioSpectrum Asia","headline":"Using rice grains as factories for producing medicines","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}